
| |
| |
Briefing Papers - Disclosure of origin of 'genetic resources'
September 2005 The existing briefing paper was reviewed by the CIPA Life Sciences Committee in July 2010, and an updated version will be posted shortly.
- Intellectual Property protection for new plants
April 2009 Modern agriculture requires improvements in the technology of plant breeding to produce new varieties of plant which yield crops having improved resistance to diseases, pests, and other stresses...
- Patentability of stem cells in Europe
May 2011 Stem cell research is giving scientists the power to create new tools which might one day be used to repair or replace tissues, for example, to repair spinal cord injuries, to treat diabetes, Parkinson's disease, osteoporosis and heart attacks. However, one technically favoured source of human stem cells is the early human embryo, and such embryos are destroyed when the stem cells are removed. This raises significant moral and ethical questions regarding whether society is willing to accept the sacrificing of such embryos, if necessary, for research and/or therapeutic uses.
- Patenting in the pharmaceutical industry - supplementary protection certificates
October 2009 The Chartered Institute of Patent Agents strongly supports an all-industry approach to patenting inventions, including inventions made in the pharmaceutical industry...
- Patentability of animals
April 2008 Industrially useful inventions are generally patentable if they are novel and involve an inventive step (i.e. they are surprisingly different, rather than simply a development, modification or combination of previously known features)...
- Patenting of human gene sequences
June 2006 The technology known as "genetic engineering" involves the transfer of genetic information from one organism to another so that the modified organism can carry out the function for which the transferred genetic information provides the instructions...
- The United Nations Bio-Diversity Convention
February 2009 The existing briefing paper was reviewed by the CIPA Life Sciences Committee in July 2010, and an updated version will be posted shortly.
|
|
|
|